⌛ Did you miss ProPicks’ 13% gains in May? Subscribe now & catch June’s top AI-picked stocks early.Unlock Stocks

Europe stocks higher early on; drugmakers rise

Published 09/01/2009, 03:12 AM
Updated 09/01/2009, 03:15 AM
UK100
-
NOVN
-
XTA
-
AZN
-
ENRC
-
AAL
-
BHPB
-
HG
-

LONDON, Sept 1 (Reuters) - European shares were higher in early trade on Tuesday, with investors sticking to defensive drugmakers as they await U.S. pending home sales.

By 0706 GMT, the pan-European FTSEurofirst 300 index of top shares was up 0.5 percent at 976.69 points.

"Anything that shows new home sales rising and inventories falling is good as it strengthens the case home prices are stabilising," said Bernard McAlinden, market strategist at NCB Stockbrokers, referring to the U.S. data.

The U.S. National Association of Realtors releases Pending Home Sales for July at 1400 GMT. Economists in a Reuters survey expect a 2.0 percent rise compared with a 3.6 percent increase in the previous month.

Drugmakers were the biggest risers on the index. GlaxoSmithKline, AstraZeneca, Novartis and Roche were 0.7 to 1.6 percent higher.

On the downside, miners were lower as copper slipped 2.3 percent following a selloff in Shanghai. Anglo American, Antofagasta, BHP Billiton, Eurasian Natural Resources Corporation and Xstrata were down 0.3 to 2.1 percent.

Across Europe, the FTSE 100 index was up 0.1 percent, Germany's DAX was 0.5 percent higher and France's CAC 40 was up 0.8 percent. (Reporting by Joanne Frearson)

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.